Amid soaring interest in AI, this market map breaks down the AI companies helping pharma giants discover new drug targets and carry out clinical trials more efficiently.
AI could create the next life-saving drug.
Pharma players are already using AI to understand viral structures, identify small molecule drug candidates, and design novel proteins. They’re also embracing the technology as a way to streamline clinical trials, from patient recruitment to protocol design.
The space has seen a flurry of investment activity and consolidation this year. Biopharma player Recursion, for instance, acquired 2 startups — Cyclica and Valence — to boost its generative AI capabilities, while XtalPi, which applies AI to small molecule drug discovery, announced a partnership with Merck and a $250M deal with Eli Lilly.
Using CB Insights data, we identified 154 AI companies across 14 tech markets — from real-world data to biomedical NLP — helping pharma companies transform drug discovery and clinical trials.
Want to see more research? Join a demo of the CB Insights platform.
If you’re already a customer, log in here.
